Evidence map›Paper›PMID 41887543›Full record

ArticleBrain, behavior, and immunity2026

Microglia promote vascular remodeling in a mouse model of chronic stress.

Zachary Hage, Miguel M Madeira, Kimberly Nnah, Dimitris Koliatsis, Alexandros G Kokkosis, Laurel E Schappell, Neil A Nadkarni, Stella E Tsirka

Abstract read
In one paragraph

Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zachary HageProgram in Molecular and Cellular Pharmacology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Scholars in Biomedical Sciences Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
Miguel M MadeiraProgram in Molecular and Cellular Pharmacology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Scholars in Biomedical Sciences Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Neurology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
Kimberly NnahScholars in Biomedical Sciences Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Program in Neuroscience & Department of Neurobiology and Behavior, Stony Brook, NY, USA.
Dimitris KoliatsisDepartment of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
Alexandros G KokkosisProgram in Molecular and Cellular Pharmacology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Scholars in Biomedical Sciences Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
Laurel E SchappellProgram in Molecular and Cellular Pharmacology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Stony Brook Medical Scientist Training Program, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.
Neil A NadkarniProgram in Molecular and Cellular Pharmacology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Neurology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
Stella E TsirkaProgram in Molecular and Cellular Pharmacology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Department of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; Scholars in Biomedical Sciences Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA. Electronic address: styliani-anna.tsirka@stonybrook.edu.

Funding

Training Program in Pharmacological SciencesT32GM007518 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GARCIA-DIAZ, MIGUEL · 1985 to 2021
$5.4M
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention - Diversity Administrative supplement for Kimberly NnahR01MH123093 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI DELORENZO, CHRISTINE, PARSEY, RAMIN V. · 2020 to 2024
$3.8M
Training Program in Pharmacological SciencesT32GM144304 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI HOLLY A COLOGNATO · 2022 to 2026
$1.8M
Defining the Spatiotemporal Underpinnings of Neutrophil Recruitment, Microvascular Flow, and Oxygenation in Ischemic StrokeK08NS121597 · NINDS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Neil Avadhoot Nadkarni · 2023 to 2026
$1.1M
Scholars in BioMedical Sciences (SBMS) Training ProgramT32GM148331 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Styliani-Anna (Stella) E Tsirka · 2024 to 2026
$695k
Scholars in BioMedical Sciences (SBMS) Training ProgramT32GM127253 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI TSIRKA, STYLIANI-ANNA (STELLA) E · 2018 to 2022
$689k
American Heart Association-American Stroke Association 25PRE1378352NIGMS NIH HHS T32 GM007518NIGMS NIH HHS T32 GM127253NIGMS NIH HHS T32 GM144304NIGMS NIH HHS T32 GM148331NIMH NIH HHS R01 MH123093NINDS NIH HHS K08 NS121597
6 · The paper itself

Abstract

Major Depressive Disorder (MDD) is a debilitating mental illness affecting over 350 million people globally. Chronic stress is a major risk factor for MDD and is associated with increased vascular dysfunction and cardiovascular disease. While inflammation is often implicated in these pathologies, the specific interactions between immune cells and the cerebral vasculature in the context of chronic stress remain poorly understood. We employed a chronic social defeat stress (CSDS) model in mice to investigate immune-vascular interactions in the medial prefrontal cortex (mPFC). We also used a subthreshold stress model to assess the temporal sequence of microglial and vascular changes. To explore the role of endothelial signaling, we utilized a CD31 knockout model. Microglial activation, vascular morphology, and immune cell infiltration were assessed using immunohistochemistry and functional assays. Chronic stress induced microglial activation and increased microglia-vessel interactions in the mPFC, which were associated with impaired vascular morphology. These interactions were observed to precede vascular changes in the subthreshold model. Cytokines released by interferon (IFN)γ-stimulated microglia promoted macrophage infiltration into the brain. Deletion of endothelial CD31, a key mediator of transendothelial migration, prevented macrophage recruitment and protected against inflammatory, vascular, and behavioral deficits associated with CSDS. Our findings highlight important immune-vascular interactions in chronic stress, where microglia contribute to cerebrovascular remodeling and facilitate macrophage infiltration via CD31-dependent pathways. These interactions may underlie the pathophysiology of MDD and its vascular comorbidities, offering potential therapeutic targets.

Indexed as

MicrogliaStress, PsychologicalVascular RemodelingAnimalsBrainChronic DiseaseCytokinesDisease Models, AnimalInflammationMacrophagesMajor Depressive DisorderMaleMiceMice, Inbred C57BLMice, KnockoutPlatelet Endothelial Cell Adhesion Molecule-1CytokinesPlatelet Endothelial Cell Adhesion Molecule-1Blood VesselCD31Chronic StressEndothelial CellInflammationMacrophageMajor Depressive DisorderMicrogliaPECAM

Identifiers

PMID41887543
PMCPMC13663258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.